Classifications

• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
  • A61K9/0007—Effervescent
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K31/00—Medicinal preparations containing organic active ingredients
  • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
  • A61K31/19—Carboxylic acids, e.g. valproic acid
  • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
  • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
  • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
  • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
  • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
  • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0012—Galenical forms characterised by the site of application
  • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
  • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
  • A61K9/0058—Chewing gums
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
  • A61K9/00—Medicinal preparations characterised by special physical form
  • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
  • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P25/00—Drugs for disorders of the nervous system
  • A61P25/04—Centrally acting analgesics, e.g. opioids
• • A—HUMAN NECESSITIES
  • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
  • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
  • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]

Definitions

• organoleptically acceptable solid oral formulations of S(+)-ibuprofen are those which can contact the taste receptors of the recipients mouth and which are generally acceptable to the senses of the recipient, particularly the sense of taste.
• organoleptically acceptable formulations of this invention are those solid oral formulations in which the S(+)-ibuprofen component does not have the unpleasant, bitter taste normally associated with a racemic mixture of ibuprofen.
• This invention relates to organoleptically acceptable formulations of ibuprofen.
• the racemic mixtures of ibuprofen, a widely used analgesic and antipyretic, are generally considered to be bitter and not sufficiently palatable for most types of administration which allows the recipient to taste the ibuprofen mixture.
• Some flavoring agents such as chocolate, banana, orange, lemon, licorice, root beer and raspberry flavorings, have been proposed for bitter tasting drugs, but they are generally not dependable in masking the disagreeable taste. Bitter properties are generally difficult to mask successfully if they do not mimic the expected natural taste of the flavoring agent. For this reason, pharmaceuticals with a bitter taste, such as ibuprofen, are not particularly sought for many oral dosage forms of administration, such as chewable tablets and oral liquids.
• Ibuprofen is sold under the Advil® name by Wyeth-Ayerst Laboratories, a Division of American Home Products Corporation. Wyeth-Ayerst Laboratories also sells Children's Advil® Suspension, which is a sucrose-sweetened, fruit-flavored liquid suspension designed for oral use.
• Ibuprofen is ( ⁇ )-2-(p-isobutylphenyl)-propionic acid, also known as ⁇ -Methyl-4-(2-methylpropyl)benzene-acetic acid; p-isobutylhydratropic acid; or 2-(4-isobutylphenyl)propionic acid, having the structure below: ##STR1##
• Ibuprofen is a non-steroidal anti-inflammatory agent (NSAID) which is known to possess analgesic and antipyretic activities. It is useful in the treatment of pain and inflammation associated with various maladies, including the common cold, toothaches, headaches, backaches, menstrual cramps (Dysmennorhea), the muscular aches and pains associated with Premenstrual Syndrome, rheumatoid arthritis and osteoarthritis, as well as in the reduction of fever.
• NSAID non-steroidal anti-inflammatory agent
• Ibuprofen has become widely used in prescription and over-the-counter formulations for the treatment of pain associated with inflammation, both minor and chronic.
• One of its drawbacks, however, is that it has an unpleasant, bitter taste which tends to limit its acceptability in many oral dosage forms.
• methods of alleviating this limitation have included attempts at masking the bitter taste with flavored and/or sweetened mediums or by coating the ibuprofen with substances which prevent it from contacting the taste buds during oral administration. While reducing the extent of the bitterness, these solutions do not make the use of oral ibuprofen formulations organoleptically acceptable to all ibuprofen users. In addition, these steps add to the time and expense of preparing many oral ibuprofen formulations.
• the S (+) stereoisomer of ibuprofen which may also be referred to herein as (+) 2-(p-isobutylphenyl)-propionic acid, the ibuprofen eutomer or the eutomer of ibuprofen, does not contain the unpleasant, bitter taste which the racemic ibuprofen is known to possess.
• the present invention comprises organoleptically acceptable oral formulations comprising, in whole or in part, the S(+) stereoisomer of ibuprofen.
• oral formulations include those orally administerable formulations in which the active ingredients or drugs of the formulation may normally be presented to the taste and or smell receptors of the recipient.
• Such formulations include, but are not limited to, organoleptically acceptable ibuprofen liquid solutions, suspensions, emulsions, syrups, colloids, sachets, tablets, including chewable, buccal and sublingual tablets, powders or granular compositions, effervescent formulations, cachets, troches or lozenges, pastes, foams, dentifrices and gels. Because of the use of NSAIDs in veterinary medicine, formulations which are organoleptically acceptable to animals, particularly companion animals such as cats and dogs, can be produced within the scope of this invention.
• this invention comprises an organoleptically acceptable ibuprofen formulation which comprises the ibuprofen eutomer, itself.
• This compound may be taken orally by itself for the relief described above.
• the eutomer of ibuprofen may be taken with water, fruit juices, soft drinks, milk or other liquids or beverages being used to assist in the oral administration of the drug.
• Other simplified administrations can include the administration of the eutomer to food, which may then be consumed in the normal fashion. These food-related or drink-related routes of administration may be preferred by any number of recipients, particularly children.
• the formulations of this invention containing the ibuprofen eutomer also contain an acidic component of sufficient amount to maintain the pH of the formulation below 7, preferably between 2 and 6.
• Pharmaceutically acceptable acids for use in these formulations include, but are not limited to, commonly used food acids such as citric acid, tartaric acid, malic acid, funaric acid, lactic acid, adipic acid, ascorbic acid, aspartic acid, erythorbic acid, glutamic acid, and succinic acid.
• ibuprofen eutomer-containing compositions of this invention may be used in the manner and for the dosages suggested for the ibuprofen tablets and capsules presently on the market. It will be understood by those skilled in the art that ibuprofen, like other NSAIDs, may exhibit a variation in response from individual to individual. Therefore, the recommended initial therapeutic dose should be one which is likely to be effective for the majority of recipients, with the dosage being adjusted thereafter according to the beneficial and adverse effects observed by the recipient.
• the ibuprofen eutomer of this invention should be administered in the smallest dose which will effectuate the desired physiological result.
• This may comprise a single dose of from as little as 5 or 10 mg, such as in the case of small infants, to 1 g or more for larger adults, preferably from 50 mg to 800 mg, most preferably 100 to 400 mg, of the ibuprofen eutomer for relief of minor pain.
• Suggested dosages for pain associated with more chronic problems would range from approximately 600 to 3200 mg per day in regimens of 300 mg q.i.d. or 400 mg, 600 mg or 800 mg, t.i.d. or b.i.d.
• the formulations described herein may include sweetening or flavoring agents to increase the overall flavor, taste and desirability of the formulation.
• sweetening agents may include all pharmaceutically acceptable sweetening agents including, but not limited to, molasses, glycine, corn syrup, sugars, such as sucrose, glucose, fructose and confectioner's sugar, sorbitol, saccharin, saccharose, saccharin sodium, saccharin calcium, aspartame (available under the Nutrasweet® trademark, Nutrasweet Company, Deerfield, Ill.), stevioiside, neohesperidyl dihydrochalcone, glycyrrhiza, perillaldehyde, xylitol, dextrose, mannitol and lactose.
• the formulations herein may also include pharmaceutically acceptable excipients, fillers, diluents, lubricants, disintegrants, suspending or stabilizing agents, and binding agents including, but not limited to, magnesium stearate, sodium lauryl sulfate, microcrystalline cellulose, polyvinylpyrrolidone, gelatin, alginic acid, acacia gum, sodium citrate, complex silicates, calcium carbonate, glycine, dextrin, sucrose, sorbitol, dicalcium phosphate, calcium sulfate, lactose, kaolin, mannitol, sodium chloride, talc, dry starch (e.g. corn, potato or tapioca starch) and powdered sugar.
• excipients e.g. corn, potato or tapioca starch
• the formulations of this invention would include powdered or granular dosage formulations containing the ibuprofen eutomer.
• the eutomer can be taken orally, by itself, in a powdered or granular form. The recipient may wish to place such a powdered or granular formulation into his mouth and wash it down by drinking a liquid or eating a solid food.
• organoleptically acceptable powdered pharmaceutical components may be compounds with additional pharmaceutical activities or fillers, sweeteners, etc. as described herein. It will be understood that any dosage of ibuprofen eutomer can be administered in this way, with the volume of additional components being limited only to the amount found acceptable to a recipient.
• organoleptically acceptable oral liquid ibuprofen dosage forms can be formulated and utilized, most particularly with an acidic component.
• Such liquid formulations may be created with a water base.
• oral liquids may include any oral liquid formulations utilizing the eutomer of ibuprofen, including the mere incorporation of the desired dose of ibuprofen eutomer into a normally consumed amount of beverages and drinks including for example, but not limited to, carbonated or non-carbonated water, fruit juices, coffee, tea, soft drinks and milk.
• Such liquid formulations also preferably contain an acidic component, as described herein, sufficient to maintain the pH of the liquid formulation below 7, preferably between 2 and 6.
• the oral liquid comprises from about 0.8% to about 4% ibuprofen eutomer weight by volume of the total composition, about 0.1% to about 2% weight by volume of the total composition of suspension stabilizing agents, about 20% to about 70% by weight of the total composition of one or more flavoring agents, about 30% to about 70% weight by volume of the total composition of water, with the composition containing a pharmaceutically and organoleptically acceptable food acid, such as citric acid or phosphoric acid, in an amount of 0.1% to about 2% weight by volume.
• the suspending agents include xanthan gum, microcrystalline cellulose, sodium carboxymethylcellulose and polysorbate 80. Examples 1 and 2, below, describe how two such formulations may be produced.
• a first portion of this oral liquid formulation may be prepared by first placing the Sorbitol solution and glycerin portions into a jacketed kettle equipped with a stirrer. Then the sodium carboxymethyl cellulose component is sprinkled onto the solution and mixed for 10 minutes until it becomes completely wet. The mixture should then be heated to about 70° C. and mixed until the gum is completely hydrated, followed by cooling of the mixture to 45° C. and addition of the polysorbate 80 component. Mixing is continued while cooling the mixture to 30° C. The ibuprofen eutomer is sprinkled slowly into the mixture and mixing continued for 15 minutes.
• a second portion is then created by placing the required amount of water into a container equipped with a propeller-type mixer and adding slowly and hydrating the xanthan gum by mixing with a high shear for approximately 25 minutes. This should be followed by placing into a separate mixing vessel, equipped with a propeller type mixer, a quantity of water equivalent to about 30% to 40% by volume of the total batch (4500 to 6000 mL). The microcrystalline cellulose may then be sprinkled onto the water and mixed at medium shear for about 30 minutes to completely disperse the cellulose.
• the required amount of the xanthan gum solution from the first portion, above, is added to the cellulose suspension with mixing for about 15 minutes or until a uniform suspension is obtained. This is followed by slow addition of the sucrose with mixing for about 15 minutes, or until no sucrose particles are observed. Coloring agents, such as the Red FDC 40 Color mentioned above, may be added and mixed until dispersed throughout the mixture.
• Another example of an oral liquid formulation utilizing S(+) ibuprofen is the following:
• This preparation may be prepared by measuring the sorbitol solution and glycerin into a jacketed kettle equipped with a stirrer. Into this solution is sprinkled the sodium carboxymethylcellulose, which is mixed for 10 minutes or until all of the particles are completely wet. The resulting mixture is then heated to about 70° C. and mixed until the gum is completely hydrated, after which the mixture is cooled to 45° C. and the Polysorbate 80 is added. Mixing is then continued while the mixture is cooled to 30° C. The ibuprofen eutomer is then added slowly into the mixture and mixing is continued for 15 minutes to produce what is referred to below as the ibuprofen slurry.
• a second solution which may be referred to as the xanthan gum solution, is prepared first in the form of a 1% by weight xanthan gum solution in water.
• the xanthan gum should be added slowly to the water and mixed at high shear for approximately 25 minutes.
• Into a separate mixing vessel equipped with a mixer is placed a volume of water equivalent to 30% to 40% weight by volume of the total batch (4500 to 6000 ml).
• the microcrystalline cellulose is then sprinkled onto the water and mixed at medium shear for 30 minutes or until the microcrystalline cellulose is completely suspended.
• the required amount of xanthan gum solution is then added to the microcrystalline cellulose suspension with mixing for 15 minutes or until a uniform suspension is obtained.
• sucrose is then added slowly to the second solution with mixing for 15 minutes or until no sucrose particles are observed.
• the coloring agents may then be added.
• the required amount of the ibuprofen slurry is then added slowly and mixed for 15 minutes.
• the sodium benzoate, disodium edetate and citric acid are then sequentially added and mixed for 5 minutes following each addition.
• the hydrochloric acid component is added with mixing until the formulation reaches a pH from about 2.5 to about 3.5. The remainder of the water is then added with mixing until the formulation is homogenous.
• Chewable tablets containing the ibuprofen eutomer and falling within the scope of this invention will be understood to include those chewable tablet formulations known in the art to be pharmaceutically and organoleptically acceptable. These formulations will include those having a) ibuprofen eutomer in the dosage amounts described herein; b) from about 5 mg to about 400 mg, preferably from about 10 mg to about 200 mg, of a solid acidifier component, such as the food acid components described herein; and c) from about 50 mg to about 5 g, preferably from about 100 mg to about 1 g, of a pharmaceutically and organoleptically acceptable excipient, such as dextrates, maltodextrins, lactose, modified food starches, aluminum stearate, chewing gum base, and compactable food grade sugars, as well as other materials suitable as filler and carnier agents.
• these chewable tablet formulations may contain up to about 100 mg of a pharmaceutically acceptable glidants or lubricants.
• Chewable tablets of this formulation may be prepared by first blending the ibuprofen eutomer, sorbitol, citric acid, polyethylene glycol 9000, and spearmint flavor in a blender for about 10 minutes. This is followed by passing this newly formed blend through a mill using a #14 screen, medium speed, knives forward. Then add the magnesium stearate to the mixture and blend for about one (1) minute. This blended mixture should then be compressed into tablets of the correct weight using a 5/8" flat, round, beveled edge punch and die set.
• the organoleptically acceptable ibuprofen eutomer formulations of this invention also include effervescing or foaming formulations. These formulations include any pharmaceutical composition which utilizes the ibuprofen eutomer in an effervescing formulation, particularly those containing an effervescing or foaming combination of an organoleptically acceptable acid, such as a food grade acid, and a carbonate.
• Pharmaceutically acceptable acids for use in these formulations include, but are not limited to, citric acid, tartaric acid, malic acid, fumaric acid, adipic acid, ascorbic acid, aspartic acid, erythorbic acid, glutamic acid, and succinic acid.
• Glycine may also be used as part of the acidic component, if desired, but it is most preferred that glycine not comprise the majority of the acidic component. It is most preferred that the acidic component of these effervescent formulations exceed that of the carbonate component to create an effervescent solution with a pH below 7, more preferably below 6.
• the carbonates may include any effervescing or foaming carbonate which is pharmaceutically and organoleptically acceptable, including, but not limited to, sodium bicarbonate, potassium carbonate, sodium carbonate, calcium carbonate, ammonium carbonate, magnesium carbonate, and the like. It is understood that the acidic and carbonate components of these formulations may comprise one or more of the acceptable acids or carbonates.
• the effervescent or foaming formulations of this invention comprise the active ibuprofen eutomer, plus any active amounts of the acid and carbonate components.
• the portions of these three components comprise a) the desired amount of the ibuprofen eutomer, b) from about 0.5% to about 50% by weight of the acid component and c) from about 0.5% to 50% by weight of the carbonate component.
• a single dose of this drug may comprise a) 50-800 mg of (+)-2-(p-isobutylphenyl)-propionic acid, b) 1-8 g citric acid, or an equivalent amount of one or more of the other acceptable acids described herein, and c) 1-8 g of sodium bicarbonate, or an equivalent amount of one or more of the acceptable carbonates described herein.
• the components of these formulations may be varied depending upon the required dosage of the drug, the desired amount of effervescence or foaming to be created, as well as the pH of the liquid into which the formulation will be added.
• the effervescent or foaming formulations of this invention may include any additional pharmaceutically and organoleptically acceptable components, including, but not limited to, fillers, flavoring agents, coloring agents, sweetening agents, binders, pharmaceutically acceptable odor enhancing agents, perfumes, etc. These formulations may also include other pharmaceutictlly active agents, such as analgesics, antihistamines, antacids, anti-gas agents, etc. Examples of effervescent or foaming formulations within the scope of this invention include the following:
• One hundred dose batches of an effervescing or foaming powder of this invention can be made by mixing together any of the following combinations, with or without additional components:
• Step #1 After Step #1 all processes to be accomplished in an environment which does not exceed 30% relative humidity.
• Example #8 replacing Item #5 with dry orange flavor powder (from MacAndrew & Forbes Co., Camden, N.J. 08104) and replacing Step #6 of Example 8 with the following two steps:
• Step #6 Place the powder obtained from procedure Step #5 in a fluidized bed tower and when the powder is suspended with air, add enough water spray to create granules approaching 10 mesh in size.
• Step #7 Add heat to dry the granules and remove to a not greater than 25% relative humidity area to package in hermetic packets at 2.5 g each.
• compositions of this invention may take are the rapidly dissolving or disintegrating dosage forms described in U.S. Pat. No. 4,371,516, the disclosure of which is incorporated herein by reference. These forms are preferably soluble solid forms which are designed to break down in a matter of seconds upon contact with liquids, such as water or the saliva of the recipients mouth. These forms preferably disintegrate within 10 seconds of contact with liquids.
• Such formulations are especially useful for administering medicines to pediatric or geriatric patients or others who may not be receptive to the treatment and who may attempt to spit out the medicine or hide a non-disintegrating form in their mouth until it can be thrown away later.
• 75 individual 50 mg rapidly disintegrating doses of the ibuprofen eutomer can be prepared in the following manner:
• a hydrolyzed gelatin solution is prepared by dissolving 30.0 grams of gelatin B.P. in 1,000 ml of purified water with the aid of heat and constant stirring. The resulting gelatin solution is then autoclaved at 121° C. and 15 p.s.i. for one hour. The gelatin solution is then allowed to cool to room temperature.
• the +)-2-(p-isobutylphenyl)-propionic acid utilized be in the form of a micronized powder to eliminate the potential for the perception of a gritty texture as the formulation disintegrates in the recipient's mouth.
• the +)-2-(p-isobutylphenyl)-propionic acid is in the form of a micronized powder comprising particles of 50 microns or less.
• This formulation may be produced in depressions on a 220 ⁇ 330 mm p.v.c. sheet containing 150 cylindrical depressions, each depression being about 0.7 cm deep and about 1.4 cm in diameter, which has been cooled with solid carbon dioxide.
• the formulation may be produced by suspending the ibuprofen eutomer in the water containing the sodium alginate, Dextran and aspartame listed above with the use of ultrasonic vibrations. 0.75 ml of the suspension can then be placed into each of the p.v.c. sheet's depressions, where they can be freeze dried to complete the rapidly disintegrating solid formulation.
• a rapidly disintegrating solid formulation may be produced with the components listed above and the carbon dioxide cooled p.v.c. sheet described in the previous example. This may be done by adding the polyvinylalcohol to about 500 ml of hot distilled water, which is then allowed to cool. The polyvinylpyrrolidine, sucrose and Tween 80 can then be added and the mixture shaken to dissolve all of the solids. The ibuprofen eutomer is added and dispersed with ultrasonic vibration. This mixture should then be brought to the final volume of 1000 ml by the addition of distilled water. 0.75 ml of this solution may then be added to each depression for freeze drying to the final solid formulation.
• Buccal formulation containing the ibuprofen eutomer of this invention may be produced by the steps set forth in U.S. Pat. No. 4,764,378 (Keith et al.), the contents of which are incorporated herein by reference. It is most preferred that these buccal formulations have incorporated therein an acidic component, such as a micronized solid food acid. Such a food acid may comprise from about 0.1-2.0% of the weight of the final buccal formulation, though more acid may be added if desired.
• an acidic component such as a micronized solid food acid.
• Such a food acid may comprise from about 0.1-2.0% of the weight of the final buccal formulation, though more acid may be added if desired.
• Lozenge or troche formulations containing the ibuprofen eutomer may also be prepared for any dosage described herein by methods known in the art.
• such lozenges may be prepared by molding and subsequently drying by evaporation a concentrated syrup containing the ibuprofen eutomer, with thickening agents such as acacia or tragacanth gums added, if necessary.
• This type of lozenge is often referred to as a candy mass lozenge or troche.
• candy mass lozenges can be made for any dosage of ibuprofen eutomer described herein. Described below is a formulation useful for producing lozenges containing 100 mg of ibuprofen eutomer.
• lozenges can be produced by adding the sucrose, cream of tartar (optional) and corn syrup listed above to a stock pot with mixing, followed by boiling to dissolve the sucrose and cream of tartar. These components should be removed from the heat when a stiff boil is achieved, which will occur at about 290° F., and about 30% of the original volume is lost to evaporation. These components should be mixed until the mass cools to approximately 280° F. At this point the citric acid and ibuprofen eutomer should be added to the mass with mixing to create a homogenous dispersion. When the batch cools to about 190° F. the mass can be rolled into a rope or columnar shape and cut into 4 g pieces. These pieces may then be placed on a mesh to cool to ambient temperatures.
• a more readily disintegrating lozenge or troche form may be made using 9200 g of compressible sugar, such as Dipac® brand compressible sugar (Domino Sugar Co., New York, N.Y.), and the amounts of cream of tartar (optional), citric acid and ibuprofen eutomer (or other preferred dose of the ibuprofen eutomer) described above. These components may be homogeneously mixed and compressed into lozenges of the desired size, such as the 4 g size described above.
• sucrose or lactose may be thoroughly mixed with a suitable binding agent, such as about 525 g of sodium alginate, and a pharmaceutically suitable granulating fluid to create a wet mass.
• a suitable binding agent such as about 525 g of sodium alginate
• a pharmaceutically suitable granulating fluid to create a wet mass. This wet mass may be passed through a granulating mill and compressed into lozenges of the desired size.
• Dentifrice compositions known in the art may have S(+) ibuprofen, preferably with an additional acidic component, incorporated therein for use in the prevention or reduction of bone loss and/or for promoting regrowth of bone previously lost.
• dentifrices herein are intended to include any dental formulations that may be used in the treatment and maintenance of teeth and mouth tissues. These include, but are not limited to pastes, gels, powders, granular compositions, liquids, etc.
• An example of a toothpaste within the scope of this invention can be produced by slowly adding the non-aqueous components listed below to water, followed by conventional mixing with a roller mill.
• the organoleptically acceptable dentifrices within the scope of this invention may include any of the known dentifrice formulations, preferably with an existing or added acidic component.
• Paste formulations of this type may contain, for example, by weight from 10-50% of an abrasive system, 0.5-10% thickeners, 10-80% humectant, 0.1-1% sweetener, 0.05-2% flavoring agents, 0.001-0.02% coloring agents, 1-7.5% surfactant, 0.1-0.8% antimicrobial preservatives, and 0.01-5% acidifiers.
• Abrasive components of these formulations can include calcium pyrophosphate, hydrated silica, insoluble sodium metaphosphate, organic polymers, alumina trihydrate, dicalcium phosphate dihydrate, dicalcium phosphate anhydrous and calcium carbonate.
• Thickeners can include silica aerogel, pyrogenic silica, silica precipitates, carboxymethylcellulose, carboxy vinyl polymers, xanthan gum and carrageenan.
• Humectants of use include sorbitols, glycerine and polyethylene glycols.
• Useful sweeteners include saccharin, xylitol, cyclamate, aspartame and thaumatin.
• Flavoring agents can be modified according to taste and market acceptability, but include peppermint, spearmint, wintergreen, cinnamon, and anise flavors, as well as essential oils. Any FDA approved coloring agents may be chosen for incorporation into such dental formulations.
• Surfactants may include sodium laurylsulfate, sodium laurylsarcosinate, pluronics, tweens, sodium cocomonoglyceride sulfonate, sodium dodecylbenzene sulfonate, and dioctylsodiulll sulfosuccinate.
• Antimicrobial agents and preservatives for use in this art include parahydroxybenzoates, sorbic acid and benzoic acid. Acid components for these forms include the food acids described herein, including lactic acid, citric acid, phosphoric acid and tartaric acid.
• An example of such a dentifrice can be formed from the following ingredients.
• the pH of this formulation not be lower than about 5.0.
• Sodium monofluorophosphate is an appropriate fluoride source for use within this desired pH range.
• Another organoleptically acceptable formulation within the scope of this invention are chewing gum types of formulations. It will be understood that these types of formulations can be created by incorporating the ibuprofen eutomer, most preferably along with a suitable acidic component, into any of the organoleptically acceptable chewing gum bases.
• An example of a chewing gum formulation of this invention can be made with the components seen below in Example 19.
• the components listed above can be combined into a chewing gum formulation by warming the gum base ingredients to a softened stage, followed by separate addition steps for the acidifier, sweetener, ibuprofen eutomer and flavoring agent, with kneading to produce a homogenous mixture following each addition.
• the final homogenous chewing gum formulation can then be rolled out with a sizing machine and cut into 3 g pieces using finely powdered sucrose to facilitate handling, followed by standard wrapping and packaging. It is understood that other chewing gum formulations may be utilized within the scope of this invention and that the components of the formulation described above may be replaced with equivalent amounts of other functional components, including those described herein for use with other formulations.
• organoleptically acceptable formulations is important in veterinary applications. While this is true for any mammal which a veterinary specialist may recommend the use of an NSAID, it is particularly true in the case of companion animals, such as dogs and cats, where owners and handlers appreciate the relative ease of administering readily accepted oral dosage formulations, as opposed to those which must be administered with animal restraint techniques.
• Veterinary formulations of this invention include any of the solid or liquid dosage forms mentioned above which may also be given to animals. These formulations may be incorporated into an animal's food or drink or given as a separate pharmaceutical entity. If given separately, it is recommended that the formulation contain an ingredient, preferably a taste ingredient, which is normally found appealing to the animal in question. For example, with cats and dogs a flavor base component of liver digest, seafood digest, poultry digest, desiccated liver, soya flour, sugar, cod liver oil, soy bean meal, fish meal, bone meal, yeast, wheat germ meal, fish meal or other known food bases or a combination thereof may be used. Such ingredients may be used as flavoring agents in the formulations listed above or they may be used as fillers in place of other materials described herein. It will be understood that the percentages of ingredients in animal-oriented oral formulations of this invention will be determined in large part by the size of the animal and the size of the desired formulation. For instance, a relatively small chewable tablet may consist of a mixed and compressed combination of the following:
• the amounts of the components may be increased as desired, such as with the following formulation:
• these formulations also contain an acidic component, such as a solid food acid.
• an acidic component such as a solid food acid.
• a food acid such as citric or malic acid can comprise from 1-5% of the weight of the formulation, though the amount of acidic component may be raised if desired.
• Another chewable solid formulation which may be useful for animal administration would be the following:
• Another chewable tablet formulation for use with companion animals can be produced with the following components and methods. While this example shows the production of 200 mg tablets containing the ibuprofen eutomer, it will be understood that any dosage required can be formulated in this type of formulation.
• Chewable tablets of this formulation can be produced by blending the ibuprofen eutomer, sodium starch glycolate, spray dried lactose, fumaric acid, desiccated liver and dried yeast in a suitable mixer until uniform. Then 2/3 of the quantity of aluminum stearate can be added to a portion, such as approximately 10%, of the mixture of ingredients just described with mixing until uniform. The remaining mass of the ingredients can then be added with sufficient mixing to distribute the aluminum stearate-containing mass. This blended mixture may then be slugged medium hard and sized through a rotary granulator using a #10 screen. The remainder of aluminum stearate can then be added to the granulated mixture with mixing. The final tablets of this formulation can be compressed into tablet form, such as by using a 1 1/16" flat face punch at a hardness of from 12 to 15 SCU. Tablets of this type may be either given whole or broken into smaller sections for lower dosage deliver.

Landscapes

• Health & Medical Sciences (AREA)
• Life Sciences & Earth Sciences (AREA)
• Veterinary Medicine (AREA)
• Chemical & Material Sciences (AREA)
• General Health & Medical Sciences (AREA)
• Animal Behavior & Ethology (AREA)
• Public Health (AREA)
• Pharmacology & Pharmacy (AREA)
• Medicinal Chemistry (AREA)
• Epidemiology (AREA)
• Engineering & Computer Science (AREA)
• Chemical Kinetics & Catalysis (AREA)
• General Chemical & Material Sciences (AREA)
• Oil, Petroleum & Natural Gas (AREA)
• Physiology (AREA)
• Nutrition Science (AREA)
• Zoology (AREA)
• Bioinformatics & Cheminformatics (AREA)
• Organic Chemistry (AREA)
• Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
• Pain & Pain Management (AREA)
• Proteomics, Peptides & Aminoacids (AREA)
• Neurosurgery (AREA)
• Neurology (AREA)
• Biomedical Technology (AREA)
• Rheumatology (AREA)
• Medicinal Preparation (AREA)
• Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
• Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
• Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Applications Claiming Priority (2)

Publications (1)

Family

ID=37709653

Family Applications (1)

Country Status (22)

Cited By (25)

Families Citing this family (16)

Citations (26)

Family Cites Families (6)

• 1996
  • 1996-04-13 TW TW085104431A patent/TW442287B/zh active
  • 1996-06-10 ZA ZA9604929A patent/ZA964929B/xx unknown
  • 1996-06-10 SK SK744-96A patent/SK74496A3/sk unknown
  • 1996-06-10 CA CA002178691A patent/CA2178691A1/fr not_active Abandoned
  • 1996-06-10 IN IN1076CA1996 patent/IN182039B/en unknown
  • 1996-06-10 US US08/661,207 patent/US5780046A/en not_active Expired - Lifetime
  • 1996-06-11 NZ NZ286790A patent/NZ286790A/en unknown
  • 1996-06-11 PL PL96314731A patent/PL314731A1/xx unknown
  • 1996-06-11 CZ CZ961703A patent/CZ170396A3/cs unknown
  • 1996-06-11 AU AU55881/96A patent/AU715367B2/en not_active Ceased
  • 1996-06-11 EA EA199600028A patent/EA000046B1/ru not_active IP Right Cessation
  • 1996-06-11 EP EP96304322A patent/EP0753296A3/fr not_active Withdrawn
  • 1996-06-12 NO NO962490A patent/NO962490L/no not_active Application Discontinuation
  • 1996-06-12 HU HU9601619A patent/HUP9601619A3/hu unknown
  • 1996-06-12 BR BR9602759A patent/BR9602759A/pt active Search and Examination
  • 1996-06-12 EE EE9600068A patent/EE9600068A/xx unknown
  • 1996-06-12 MA MA24281A patent/MA23908A1/fr unknown
  • 1996-06-12 TR TR96/00498A patent/TR199600498A2/xx unknown
  • 1996-06-12 JP JP8150867A patent/JPH092949A/ja active Pending
  • 1996-06-12 CN CN96112209A patent/CN1155417A/zh active Pending
  • 1996-06-12 IL IL11863796A patent/IL118637A/xx not_active IP Right Cessation
  • 1996-06-12 AR ARP960103121A patent/AR002442A1/es not_active Application Discontinuation

Patent Citations (26)

Non-Patent Citations (2)

Also Published As

Similar Documents

Legal Events